Item 2.02 Results of Operations and Financial Condition
On January 28, 2021, Adamis Pharmaceuticals Corporation (the "Company") filed
with the Securities and Exchange Commission ("SEC") a preliminary prospectus
supplement (the "Preliminary Prospectus Supplement"), pursuant to Rule 424(b)
under the Securities Act of 1933, as amended (the "Securities Act") in
connection with a proposed public offering of shares of its common stock, which
contained information regarding the Company's preliminary estimates of its cash
and cash equivalents as of December 31, 2020. The Company preliminarily
estimates that its cash and cash equivalents as of December 31, 2020 was
approximately $6.9 million. This preliminary estimate is not a comprehensive
statement of the Company's financial results for the fiscal year ended December
31, 2020, has not been reviewed by our independent registered public accounting
firm and is subject to change upon completion of our financial statement closing
procedures. The Company expects to complete its audited consolidated financial
statements for the year ended December 31, 2020 subsequent to the completion of
the Offering. It is possible that we or our independent registered public
accounting firm may identify items that require us to make adjustments to the
estimate of our cash and cash equivalents balance set forth above and those
changes could be material. Accordingly, undue reliance should not be placed on
this preliminary estimate.
The information provided in this Item 2.02 of this Form 8-K shall not be deemed
"filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as
amended (the "Exchange Act"), or otherwise subject to the liabilities of that
section, or Sections 11 and 12(a)(2) of the Securities Act, nor shall it be
deemed incorporated by reference into any of the Company's filings under the
Securities Act, or the Exchange Act, except as expressly set forth by specific
reference in such filing.
Item 8.01 Other Events
The Preliminary Prospectus Supplement contained an updated summary description
of certain aspects of the Company's business. Accordingly, the Company is filing
this information with this Current Report on Form 8-K for the purpose of
supplementing and updating disclosures contained in the Company's prior filings
with the SEC, including those discussed in the Company's most recent Annual
Report on Form 10-K for the fiscal year ended December 31, 2019, as supplemented
by the Company's subsequent filings with the SEC. The updated disclosures are
filed herewith as Exhibit 99.1 and are incorporated herein by reference.
Item 9.01 Financial Statements and Exhibits
(d) Exhibits.
Exhibit No. Exhibit Description
99.1 Updated Summary Business Information
104 Cover page interactive data file (embedded within the Inline XBRL
document).
© Edgar Online, source Glimpses